Seroprevalence of bactericidal antibody against Neisseria meningitidis serogroup C in pre-vaccinal era: The Italian epidemiological scenario

Gasparini, Roberto; Rizzetto, Rolando; Sasso, Tiziana; Rizzitelli, Emanuela; Manfredi, Piero; Risso, Domenico; Gentile, Chiara; Atti, Marta Luisa Ciofi degli; Panatto, Donatella

doi:10.1016/j.vaccine.2009.01.076

Vaccine

2009

DOI: 10.1016/j.vaccine.2009.01.076

|View full text |Cite

Seroprevalence of bactericidal antibody against Neisseria meningitidis serogroup C in pre-vaccinal era: The Italian epidemiological scenario

Roberto Gasparini

Rolando Rizzetto

Tiziana Sasso

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2009

2015

Publication Types

Select...

Article4

Relationship

Self Cite0

Independent4

Authors

Journals

Cited by 4 publications

(1 citation statement)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These preimmunization studies revealed that approximately 20% of infants under 6 months of age and 15% of infants between 6 and 11 months of age were protected from MenC disease based on naturally derived antibodies before the introduction of the MenCC vaccine (2,8,18). Fortunately, the vaccination strategy used in The Netherlands led to a large herd immunity effect due to high-level vaccine efficacy against carriage in older age groups (11) and therefore offered protection to the very young.…”

mentioning

confidence: 99%

Absence of Neisseria meningitidis Serogroup C-Specific Antibodies during the First Year of Life in The Netherlands: an Age Group at Risk?

Voer

Klis

Niers

et al. 2009

Clin Vaccine Immunol

View full text Add to dashboard Cite

In The Netherlands, a single meningococcal serogroup C conjugate (MenCC) vaccination is administered to children at the age of 14 months. Here, we report the levels of MenC polysaccharide-specific antibodies in children at birth and at 3, 11, and 12 months of age and the presence of functional antibodies at 11 months of age, before infants receive their MenCC immunization. We observed a rapid decline in polysaccharidespecific antibodies after birth and no induction of naturally elicited polysaccharide-specific antibodies. Furthermore, at 11 months of age, no bactericidal antibodies are observed. These data indicate that these infants may be at risk in the period prior to MenCC immunization, if Neisseria meningitidis serogroup C starts to (re)circulate.Childhood immunization programs are initiated to prevent infectious diseases in children. Most countries have designed their own national immunization program (NIP), and great variations exist among different countries (7). Immunization of children at 14 months of age with the meningococcal serogroup C conjugate (MenCC) vaccine (NeisVac-C; Baxter, IL) was introduced in The Netherlands in 2002. The choice to administer the vaccine to children at this age was based on programmatic and economical reasons. In The Netherlands, only two immunizations at once are accepted by the public. This fact, taken together with the economical impact, indicated that the best opportunity to include a new vaccine in the NIP was at 14 months of age (10). Furthermore, epidemiological data supported the introduction of the MenC vaccine as a single dose with a catch-up campaign (10). Other countries in Europe adapted the United Kingdom schedule, in which immunization at first was offered at 2, 3, and 4 months of age (14). Currently, the MenCC immunization program in the United Kingdom has been changed to a schedule of administration at 3, 4, and 12 months of age (1).In addition to the introduction of the MenCC vaccine for children at 14 months of age, a catch-up program in which all children and adolescents up to 19 years of age were offered a single immunization (vaccine coverage of 94%) was carried out in The Netherlands (15). This vaccination strategy led to an almost complete disappearance of MenC disease in children, with only a few cases occurring in unvaccinated individuals, indicating a large herd immunity effect and virtually no circulation of MenC in the community (3). Given this immunization strategy, it is important to monitor the prevalence of antibodies among those age groups who may be at risk because they are not eligible to receive a MenCC vaccination yet. In the Dutch situation, these are mainly children under 14 months of age.In the present study, we evaluated the prevalence of MenC polysaccharide (PS)-specific antibodies and the serum bactericidal antibody (SBA) activities in populations of infants at various time points during the first year of life. Cord blood samples (n ϭ 41) and serum samples from children at the ages of 3 months (n ϭ 70) and 12 months (n ϭ 38) were...

show abstract

mentioning

confidence: 99%

Absence of Neisseria meningitidis Serogroup C-Specific Antibodies during the First Year of Life in The Netherlands: an Age Group at Risk?

Voer

Klis

Niers

et al. 2009

Clin Vaccine Immunol

View full text Add to dashboard Cite

show abstract

Immunogenicity of a meningococcal serogroup C conjugate vaccine in HIV-infected children, adolescents, and young adults

Bertolini¹,

Costa

Heijden

et al. 2012

Vaccine

View full text Add to dashboard Cite

Neisseria meningitidis

Kučerová¹

2015

Reviews in Medical Microbiology

View full text Add to dashboard Cite

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Seroprevalence of bactericidal antibody against Neisseria meningitidis serogroup C in pre-vaccinal era: The Italian epidemiological scenario

Cited by 4 publications

References 15 publications

Absence of Neisseria meningitidis Serogroup C-Specific Antibodies during the First Year of Life in The Netherlands: an Age Group at Risk?

Absence of Neisseria meningitidis Serogroup C-Specific Antibodies during the First Year of Life in The Netherlands: an Age Group at Risk?

Immunogenicity of a meningococcal serogroup C conjugate vaccine in HIV-infected children, adolescents, and young adults

Neisseria meningitidis

Contact Info

Product

Resources

About